First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer

Original Article from The New England Journal of Medicine — First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer

Saved in:

Bibliographic Details
Main Authors:	Carbone, David P. (Author) , Reck, Martin (Author) , Steins, Martin (Author)
Format:	Article (Journal)
Language:	English
Published:	June 22, 2017
In:	The New England journal of medicine Year: 2017, Volume: 376, Issue: 25, Pages: 2415-2426
ISSN:	1533-4406
DOI:	10.1056/NEJMoa1613493
Online Access:	Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1056/NEJMoa1613493 Verlag, Volltext: http://www.nejm.org/doi/10.1056/NEJMoa1613493
Author Notes:	David P. Carbone, Martin Reck, Luis Paz-Ares, Benjamin Creelan, Leora Horn, Martin Steins, Enriqueta Felip, Michel M. van den Heuvel, Tudor-Eliade Ciuleanu, Firas Badin, Neal Ready, T. Jeroen N. Hiltermann, Suresh Nair, Rosalyn Juergens, Solange Peters, Elisa Minenza, John M. Wrangle, Delvys Rodriguez-Abreu, Hossein Borghaei, George R. Jr Blumenschein, Liza C. Villaruz, Libor Havel, Jana Krejci, Jesus Corral Jaime, Han Chang, William J. Geese, Prabhu Bhagavatheeswaran, Allen C. Chen, Mark A. Socinski

Description
Summary:	Original Article from The New England Journal of Medicine — First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer
Item Description:	Gesehen am 21.12.2020
Physical Description:	Online Resource
ISSN:	1533-4406
DOI:	10.1056/NEJMoa1613493